Overview

An Open-Label Extension Study to Evaluate the Safety and Tolerability of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 OLE Study)

Status:
ENROLLING_BY_INVITATION

Trial end date:
2027-05-01

Target enrollment:

Participant gender:

Summary

This is an open-label, monotherapy, extension study to evaluate the safety and tolerability of SPT-300 (GlyphAllo) in adults with major depressive disorder (MDD), with or without anxious distress.

Phase:

PHASE2

Details

Lead Sponsor:

Seaport Therapeutics

Collaborator:

Premier Research Group plc